PPM-019 - Development of a population pharmacokinetic model for high-dose methotrexate in Japanese paediatric patients with acute lymphoblastic leukaemia

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPM-019
• By: NAGATA, Masashi (Department of Pharmacy, Institute of Science Tokyo Hospital, Japan)
• Co-author(s): Prof Masashi Nagata (Department of Pharmacy, Institute of Science Tokyo Hospital, Tokyo, Japan)
  Takuya Suzuoka (Department of Pharmacy, Institute of Science Tokyo Hospital, Tokyo, Japan)
  Kohta Tsuge (Department of Pharmacy, Institute of Science Tokyo Hospital, Tokyo, Japan)
  Ph.D. Yasuyoshi Ishiwata (Department of Pharmacy, Institute of Science Tokyo Hospital, Tokyo, Japan)
  Ph.D. Tsubura Noda (Department of Pharmacy, Institute of Science Tokyo Hospital, Tokyo, Japan)
  Ph.D. Toshinori Hirai (Department of Pharmacy, Institute of Science Tokyo Hospital, Tokyo, Japan)
  MD, Ph.D. Takeshi Isoda (Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan)
  MD, Ph.D. Masatoshi Takagi (Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan)
  
• Abstract:

  Background information: High-dose methotrexate (HD-MTX) is an important treatment option for paediatric patients with acute lymphoblastic leukaemia (ALL). Its use is complicated because its pharmacokinetics (PK) vary widely due to individual differences in renal function and body size. Population pharmacokinetic (PPK) modelling can be used to..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login